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Among series of novel bis-phenanthridinium – nucleobase conjugates, the adenine derivative 
revealed high (logKs = 6.9 M
-1
) and selective affinity toward complementary nucleotide 
(UMP), accompanied by specific change in the UV/Vis spectrum of phenanthridine subunits, 
differing significantly from changes caused by addition of other nucleotides. High stability 
and selectivity of adenine-conjugate/UMP non-covalent complex is according to the 
molecular modelling studies correlated to the number of  inter- and intramolecular aromatic 
stacking interactions between phenanthridinium subunits, covalently attached adenine and 
added UMP, while selectivity of adenine-conjugate toward UMP in respect to other 
nucleotides is most likely the consequence of additional hydrogen bonding between UMP and 
adenine. 
 
Introduction 
 
Efficient synthetic receptors with the capability for selective substrate binding in aqueous 
solution are important for the understanding of molecular recognition and self-assembly in 
chemical and biological systems.
1
 Detection of nucleosides and nucleotides in aqueous 
medium has paramount importance as they form the fundamental units of all the life forms. 
However, differentiation among naturally occurring nucleobases based on different hydrogen 
bonding patterns within the artificial receptor is strongly limited due to competitive hydrogen 
bonding of water;
2
 therefore among many artificial receptors reported, most of them lacked 
base selectivity. Actually, up till now there are only a few receptors able to selectively bind 
some of nucleobases in water. Lhomme et al showed the capacity of aryl - nucleobase 
conjugates to recognize certain nucleobases in water
3
, while Kimura et al demonstrated that 
zinc(II) complexes of the macrocyclic tetraamine 1,4,7,10-tetraazacyclododecane (cyclen) 
have a unique propensity to bind with deprotonated imides like thymine and, uracil, by 
forming non-covalent stable complexes in biologically relevant conditions.
4
 Moreover, 
cyclenes appended with aromatic rings such as acridine and ditopic receptors yielded binding 
constants for TMP and UMP up to K= 10
7
 M
–1
.
5
 Furthermore, some cyclo-bis-aromatic 
derivatives revealed selectivity toward certain nucleobases or basepairs due to the selective 
interactions of nucleobases with the linkers connecting aromatic subunits.
6
 Previously 
prepared bis-phenanthridinium compounds have shown at the time the highest affinity toward 
nucleosides and nucleotides but not selectivity among studied nucleobases.
7,8
 Intriguingly, 
comparison of binding constant of monomer (order of magnitude Ks=10
2
 M
-1
) with calculated 
binding constants of bis-phenanthridinium analogues (order of magnitude Ks=10
6
 M
-1
) 
revealed that not only simultaneous involvement of two monomeric units in complex 
formation was present, which should give Ks  104 M-1, but also their cooperativity in 
binding. Difference between expected Ks104 M-1 and obtained Ks106 M-1 could be 
consequence of hydrophobic effects (both, entropy- and enthalpy- driven),
9
 pre-organisation 
of bis-phenanthridinium analogues suitable for nucleobase insertion (template effect),
10
 as 
well as of the other interactions yielding significant template effect. Furthermore, earlier 
reported phenanthridinium – nucleobase conjugates were not able to differentiate among 
selected nucleotides in aqueous medium, most likely due to the strong competition of bulk 
water with expected hydrogen bonds between complementary nucleotide and nucleobase 
attached to the intercalator.
11-13 
However, the same phenanthridinium – nucleobase conjugates 
interacted highly selectively with complementary polynucleotide sequences, most likely due 
to the polynucleotide hydrophobic environment, which allowed formation of specific 
hydrogen bonds between nucleobase attached to intercalator and nucleobases of 
polynucleotide.
14,15
 
Aforementioned results suggested that nucleobase positioned within the hydrophobic cavity 
could recognize complementary nucleotide by hydrogen bonding. To achieve both high 
stability and selectivity we used bis-phenanthridinium skeleton, which, as previously noticed,
8
 
forms highly stable complexes with nucleotides by aromatic stacking interactions, to which 
we covalently attached various nucleobases. Linkers between phenanthridinium units and 
between aromatic units were chosen to allow insertion of nucleobase between two 
phenanthridinium subunits, forming in this way possible recognition spot for complementary 
nucleotides within hydrophobic cleft and additionally stabilising targeted basepair by 
aromatic stacking interactions. 
 Results and discussion 
Synthesis 
 
Since it was not possible to covalently link nucleobases directly to the only one 
phenanthridine of previously studied bis-phenanthridinium derivatives,
7,16 
novel synthetic 
strategy for building bis-phenanthridinium skeleton had to be developed. The general strategy 
that was used for the synthesis of the novel bis-phenanthridinium-nucleobase conjugates 10-
12 and reference compound 9 comprised the asymmetric or symmetric alkylation of the amino 
substituents of bis-phenanthridine 2 by mono- and dibromopropane (Scheme 1), followed by 
the introduction of nucleobase at the other end of one or both alkyl linkers (Scheme 2), and 
subsequent deprotection of tosylated compounds (Scheme 3). The compound 1 was prepared 
starting from N,N’-bis-[(4’-amino)-2-biphenylyl]-suberamid16 that was tosylated in pyridine. 
The bis-phenanthridine 2 was obtained by the Morgan-Walls reaction
17
 based on the middle 
pyridine ring formation by intramolecular electrophilic cyclisation of the bis-biphenylyl 1 
using POCl3. Then, bis-phenanthridine 2 was alkylated by large excess of mono-
bromopropane to give symmetric alkylaminobisphenanthridine 3. To get asymmetric product 
4, one of two tosyl-amino groups of 2 was alkylated in the first reaction step during seven 
days in a dark and at room temperature, using small excess (1.5 eq) of 1-bromopropane. 
Consequently, large excess of potassium carbonate and 1,3-dibromopropane were added 
dropwise in situ, in order to obtain asymmetric compound 4, while symmetric compound 5 
was obtained as side product (Scheme 1). 
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Scheme 1. The asymmetric (4) or symmetric (3, 5) alkylation of tosyl-amino substituents of 2 
by mono- and dibromopropane; (a) TsCl / pyridine / 40-50 ºC; (b1) POCl3 / 120 ºC (b2) 
NaOH / H2O; (c) Br(CH2)2CH3 (10 eq) / K2CO3 / DMF / Ar / r.t. (d1) Br(CH2)2CH3 (1,5 eq) / 
K2CO3 / DMF / Ar / r.t. (d2) Br(CH2)3Br (10 eq) / K2CO3 / DMF / Ar / r.t. 
 
The reaction of bromo-derivatives 4 and 5 with large excess of uracil or adenine was 
performed under argon atmosphere at 40-50 C in dry DMF in the presence of NaH, giving 
compounds 6-8. Under these conditions the alkylation of uracil selectively occurred at N1 
position, while adenine was selectively alkylated at N9 position. (Scheme 2). 
 
N
NTs
N
TsN R1 Br
N
H
N
N
N
NH
2
N
H
NH
O
O
N
NTs
R2
TsN
N
R1
  
(CH2)4
or
  
(CH2)4
a
6           R1 =H                   R2 =1-Uracil
7           R1 =H                   R2 = 9-Adenine
8           R1 = 9-Adenine     R2 = 9-Adenine
4     R1 = H
5     R1 = Br
 
 
Scheme 2. Synthesis of conjugates 6-8. (a) NaH / DMF / Ar / 40-50 ºC 
 
Tosyl-groups were removed by heating at 100 C under acidic conditions, followed by 
neutralization using 5M NaOH aqueous solution (Scheme 3). Compounds 9-12 were found to 
be sufficiently soluble in water under acidic conditions (pH 5). 
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Scheme 3. Deprotection of compounds 3 and 6-7. (a1) H2SO4 / CH3CO2H / 80-100 ºC (a2) 
NaOH / H2O 
 Spectroscopy 
 
The UV-Vis spectra of compounds 9-12 are strongly pH dependent, exhibiting a one step 
change at pKa  6, which was attributed to the protonation of phenanthridine heterocyclic 
nitrogen.
11,18
 Due to the poor solubility of examined compounds in neutral and basic 
conditions, all further measurements were performed at pH = 5.0, with more than 90% of all 
compounds being in the protonated (phenanthridinium) form. The absorbance of compounds 
9-12 was linearly dependent on the concentration within the c=110-6 – 410-5 mol dm-3 range 
(Table 1), while at higher concentrations aggregation of chromophores, as well as some 
precipitation occurred. The compounds 9-12 exhibited fluorescence emission (Table 1) 
proportional to concentration of compound up to c = 5 × 10-6 mol dm-3. Excitation spectra 
monitored at emission maxima agree well with the corresponding UV/Vis spectra. 
A pronounced hypochromic effect of 9-12 absorption maxima in comparison to the monomer 
compound Ph-C3 (
a
H, Table 1) is most likely the consequence of intramolecular aromatic 
stacking interactions. Furthermore, comparatively weak fluorescence of referent compound 9 
is most likely caused by strong intramolecular aromatic stacking between phenanthridinium 
subunits (Table 1), while significantly stronger fluorescence of bis-phenanthridinium-
nucleobase conjugates 10-12 (in comparison to 9) could be the result of intramolecular un-
stacking of phenanthridinium subunits caused by at least partial nucleobase insertion. 
 
Table 1. Molar extinction coefficients and absorption maxima of 9-12 and monomer 
compounds 
c
Ph-C3, 
c
Ur-C3, 
c
Ad-C3, hypochromic effects (H)
a
 of 9-12 in respect to 
monomer compounds. Fluorescence emission intensities at emission maxima of compounds 
9-12. 
 
 UV/vis Fluorescence 
 max /nm 
  
(mmol
-1
cm
2
) 
a
 H (%)
  
em /nm 
b
Ii /I2  
(550nm) 
9 269 9269 85  552 1 
10 275 25497 62  565  19 
11 270 16436 75  560  14 
12 273 30526 55  558 31 
c
Ph-C3 277 29282 - 547 
c,d 
c
Ur-C3 268 9841 - - - 
c
Ad-C3 262 13733 - - - 
 
a(Na citrate/HCl buffer, pH = 5.0, I = 0.03 mol dm-3), H(hypochromic effect) = {[2  277 nm (Ph-C3) +n  277 nm (Ur-C3 or 
Ad-C3) - 277 nm (9-12] / [2  277 nm (Ph-C3) + n  277 nm (Ur-C3 or Ad-C3)]}  100; n = 0 for compound 9, n = 1 for 
compounds 10, 11; n = 2 for 12.; b For all compounds c = 2.2  10-6 mol dm-3, exc = 270 nm; relative intensities calculated at 
 = 550 nm taking 9 as a reference.; cPublished results11; dNot possible to compare due to different experimental conditions 
 
Interactions with nucleotides 
 
Interactions of compounds 9-12 with nucleotides in aqueous medium were studied by UV/Vis 
and fluorimetric titrations. Due to the low solubility of 9-12 UV/Vis titrations were performed 
using immersion probe with 5 cm light path length, which allowed measurements at 
concentration range of 10
-6
 mol dm
-3
, thus at experimental conditions comparable to 
fluorimetric titrations. It should be noted that UV/vis spectra were collected in the range  = 
260 – 300 nm, at which both, 9-12 and also nucleotides absorb light, therefore for the 
processing of the titration-induced changes in complete spectral range multivariate analysis 
program was necessary (we applied Specfit).
19
 It should be stressed that at  >290 nm adenine 
and uracil (in contrast to guanine and cytosine) do not have UV/Vis spectrum (for UV/Vis 
spectra of nucleotides see Supp. Info.) and therefore titration-induced changes in this part of 
9-12 UV/Vis spectra can be attributed only to the changes in the absorption properties of 
phenanthridinium chromophore. Titration with AMP and GMP yielded significantly stronger 
changes in the UV/Vis spectrum ( >290 nm) of the referent compound 9 in comparison to 
effects induced by UMP and CMP, most likely due to the larger aromatic surface of purine 
nucleobases in comparison to pyrimidines and consequently more efficient aromatic stacking 
interactions. 
Intriguingly, titration with UMP induced significantly stronger hypochromic effect in the 
UV/Vis spectra (at  >290 nm) of adenine-conjugates 11 and 12, if compared to referent 
compound 9 and uracil conjugate 10 (Figure 1). Even more interesting is the observation that 
titration with AMP induced clear hyperchromic effect in the UV/Vis spectra (at  >290 nm) 
of adenine-conjugates 11 and 12 (see for example Figure 2), pointing out that electronic 
absorption properties of phenanthridinium chromophores of 11 and 12 are significantly 
different upon complexation of UMP and AMP. 
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Figure 1. Changes in the UV/vis spectra (at  > 290 nm) of 9-12 (c = 2  10-6 mol dm-3) upon 
titration with UMP, done at pH = 5.0 (Na cacodylate / HCl buffer, I = 0.05 mol dm
–3
). 
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Figure 2. Changes in the UV/Vis spectrum (at  >290 nm) of 11 (c = 2  10-6 mol dm-3) upon 
titration with UMP (■) and AMP (●), done at pH = 5.0 (Na cacodylate / HCl buffer, I = 0.05 
mol dm
–3
). 
 
Changes in the UV/Vis spectra at  >290 nm of 9-12 upon titration with GMP and CMP were 
less informative due to the partial masking of changes by intrinsic UV/vis spectra of 
nucleotides. 
However, fluorimetric titrations (Figure 3) yielded more pronounced spectroscopic changes 
than UV/Vis titrations and therefore binding constants (Ks) and stoichiometries of the 
complexes determined upon processing the titration data by Specfit
19
 program are more 
accurate than those calculated from UV/Vis titrations. Nevertheless, both methods yielded 
quite comparable Ks values and for all titrations the best fit was obtained for stoichiometry 9-
12/nucleotide = 1 : 1 (Table 2). 
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Figure 3. (A) Fluorimetric titration of 11 (c=2  10-6 mol dm-3) with UMP; (B) percentage of 
formed 11/nucleotide complex calculated by Specfit.
19 
 
 
 
 Table 2. Binding constants logKs calculated from fluorimetric titrations and UV/vis titrations 
(in brackets) for 9-12/nucleotide complexes 
a,b
 
 
b 
9 10 11 12 Ph-C3 
AMP 
5-6
c 
(5.600.11) 
5.750.03 
(5-6)c 
6.340.06 
(5-6)c 
5.630.06 
(5-6)c 
1.730.02 
(nd) 
ADP >6
 c
 6.190.17 6.210.23 6.420.16 1.780.03 
ATP >6
 c
 6.140.05 6.910.23 6.630.19 2.290.02 
GMP 
5-6
 c 
(5.730.15) 
5.970.03 
(5-6)c 
5.450.04 
(d) 
5.550.08 
(d) 
1.720.09 
(nd) 
CMP 
5-6
 c 
(5-6)
c 
5.690.04 
(d) 
5.240.04 
(d) 
5.480.07 
(5-6)
c
 
1.930.08 
(nd) 
UMP 
5-6
 c
 
(5-6)
c
 
6.110.04 
(5-6)
c
 
6.890.11 
(6.230.15) 
5.860.09 
(5-6)
c
 
1.590.09 
(nd) 
a Titrations done at pH = 5 (Na cacodylate /HCl buffer, I = 0.05 mol dm–3) and logKs values are given for stoichiometry 9-
12/nucleotide = 1 : 1.; bAMP2– = adenosine monophosphate; GMP2– = guanosine monophosphate; CMP2– = cytidine 
monophosphate; UMP2– = uridine monophosphate. cDue to the small spectroscopic changes less than 10 data points were 
collected, allowing only estimation of binding constant; dSmall spectroscopic changes of complex compared to ligand and 
nucleotide resulted in linear change of absorbance, which hampered even estimation of the binding constant. 
 
The binding constants (Table 2) obtained for referent compound 9 and all studied nucleotides 
are comparable with those of previously studies phenanthridinium-based bis-intercalands and 
cyclo-bis-intercalands.
7
 It should be stressed that monomer Ph-C3 binds nucleotides 
predominantly by aromatic stacking interactions yielding logKs  2. Since compound 9 
consists of two Ph-C3 subunits linked by inert aliphatic chain, if aromatic stacking 
interactions would be dominant in 9/nucleotide complexes, the values of Ks (9/nucleotide)  
Ks (Ph-C3/nucleotide)
2
, which is actually not the case (Table 2); the obtained values of Ks 
(2/nucleotide) are more than two orders of magnitude higher, suggesting presence of 
significant template effect.
7
 Affinity of bis-phenanthridinium-nucleobase conjugates 10-12 
toward most of the studied nucleotides is comparable to the referent compound 9 affinities. 
That is also pointing toward significant template effect in respect to previously studied 
phenanthridinium-nucleobase conjugates,
11,12
 as well as phenanthridinium-bis-nucleobase 
conjugates.
13
 
Most intriguingly, the adenine conjugate 11 binds complementary nucleotide UMP with the 
binding constant (Ks 11/UMP) an order of magnitude higher than any of the binding constants 
obtained for the referent compound 9 (Ks 9/nucleotide). Moreover, the affinity of 11 toward 
UMP is significantly higher than affinity of 11 toward other nucleotide mono-phosphates 
(AMP, GMP, CMP, Table 2, Figure 3B). Such significantly stronger affinity points toward 
additional interactions between 11 and UMP (not present in the case of other nucleotide 
monophosphates). 
Furthermore, we performed isothermal titration calorimetric (ITC) studies of compound 11 
with nucleotides but at the highest possible concentrations (c(11) = 2  10-6 mol dm-3) 
observed enthalpy changes were too low for any accurate conclusion. 
 
Discussion of results of spectrophotometric titrations 
 
The UV/Vis spectrum of aromatic moiety usually reveals hypochromic effect upon stacking 
with another aromatic  -  system, although the intensity of hypochromic effect is not 
directly related to the binding constant. Therefore, hypochromic effect of 9-12 compared to 
monomer Ph-3 can be explained by intramolecular aromatic stacking of two 
phenanthridinium units, accompanied by additional stacking of covalently linked nucleobase 
(only for 10-12). However, the fact that phenanthridinium chromophores of adenine-
conjugates 11 and 12 at  >290 nm revealed much stronger hypochromic effect upon UMP 
titration in comparison to referent 9 and uracil conjugate 10 (Figure 1) suggested more 
efficient overlapping of aromatic surfaces in the case of 11/UMP and 12/UMP complexes, 
whereby one of the possible explanations is formation of an adenine-UMP basepair within the 
lypophilic pocket between two phenanthridinium subunits. Moreover, such adenine-UMP 
basepair interactions within 11/UMP and 12/UMP complexes could be correlated to the 
observed opposite changes (hyperchromic effect) in the UV/Vis spectra of adenine –
conjugates 11 and 12 at  >290 nm upon titration with UMP and AMP (Figure 2). Namely, 
the freedom of orientation of covalently bound adenine between two phenanthridinium 
subunits is very limited and basepair formation with AMP is hard to imagine. Moreover, 
surface of such adenine-adenine basepair would exceed the surface of phenanthridinium and 
therefore could not effectively yield better overlapping of aromatic surfaces in comparison to 
uracil-adenine basepair. Therefore, it is most likely that AMP and covalently bound adenine 
compete for the binding sites within 11 and 12, yielding as a final result hyperchromic effect 
at  >290 nm (UV/vis range of phenanthridinium chromophores). 
An order of magnitude higher binding constant of 11/UMP complex in comparison to any 
other 11/nucleotide complex or 9/nucleotide complex (Table 2) is also in line with proposed 
adenine-UMP basepair formation. Assuming that hydrogen bonding is contributing to the 
selectivity of 11 toward UMP, adenine of 11 should be positioned into hydrophobic 
surrounding (e.g. between phenanthridinium subunits), within which water molecules are 
mostly excluded. Otherwise, competition of extremely high excess of bulk water would not 
allow formation of hydrogen bonds between nucleobases, as previously noted for 
phenanthridinium-nucleobase conjugates.
11,12 
 
Since aforementioned UV/Vis and fluorimetric titrations cannot directly prove proposed 
adenine-UMP basepair formation and low solubility of 9-12 hampered detailed studies by 
structurally more specific methods (NMR, ITC, crystallographic studies), we have 
investigated possible conformations of such complexes by molecular modelling studies. 
 
Molecular Modelling 
 
All studied molecules were prepare in both; extended and maximally folded shape with rings 
stacked conformations, solvated, energy optimised and subjected to MD simulations (for 
details of MD simulations see ‘Methods’). During the MD simulations the extended 
conformations folded and the stacked ones slightly unfolded. However majority of molecules 
retained their folded (more or less stacking conformation), with no water molecules 
accommodated within the two phenanthridinium units, (Figure 4). Obtained structures are in 
accordance with pronounced hypochromic effect of 9-12 absorption maxima (Table 1) in 
comparison to that of the referent compound Ph-C3, whereby the strongest hypochromic 
effect of 9 (if compared to nucleobase conjugates 10-12) supports the insertion of a 
nucleobase between phenanthridinium subunits (as shown in Figure 4). Apparently impact of 
multiple aromatic stacking interactions on the hypochromicity in the UV/Vis spectrum is 
significant for the studied bis-phenanthridinium skeleton. The stacking interaction is the most 
efficient between two phenanthridinium subunits (9), insertion of another aromatic moiety 
decreases the stacking interaction intensity, whereby the effect of uracil, ie. smaller aromatic 
moiety (10) insertion is in comparison with stacking of the adenine (11, 12) less favourable. 
Although fluorescence of small molecules in water is complex phenomenon and often can not 
be directly correlated to structural properties, it is intriguing that intensity of fluorescence 
emission of phenanthridinium units of all studied nucleobase conjugates is significantly 
stronger than that of the compound 9 (Table 1), also supporting intramolecular interactions of 
nucleobases with fluorescence emitting chromophores. 
 
Figure 4. Conformations of studied compounds obtained by MD simulations 
 
Since conformations presented in Figure 4 resemble to a molecular shape of a hydrophobic 
cavity in which there is no water molecules, we considered them to be excellent starting 
points for a further modelling studies of the non-covalent complexes with nucleoside 
monophosphates AMP and UMP. 
In the initial conformation of the 9-AMP complex, used in MD simulations, adenine was 
inserted between two phenanthridinium units in a similar manner as obtained for covalently 
bound adenine conjugate 11 during MD simulations (Figure 4). Complexes 11-UMP and 11-
AMP were built in a way to enable adenine from 11 and base from mono -phosphate to form 
hydrogen bonds (Figures 6A and 7A). 
The complexes were solvated in water and the systems were geometry optimised and 
subjected to molecular dynamics simulations for 8.5 ns. The initial orientations of the bis-
phenanthridinium conjugates nucleobase and the nucleosides did not change significantly 
during the optimisation and the Watson-Crick (W-C) type of interaction was retained in 11–
UMP complex (Figure 6A). However, during the MD simulation the conformations of the 
complexes changed (see for example Figure 5). In comparison with the initial, optimized 
structures the simulation yielded less organized structure of 9-UMP complex. Difference 
between the final structures of 9-AMP and 9-UMP complexes (Supp. Info.)
†
 obtained upon 
MD simulation, clearly point out the importance of the size of aromatic part of nucleobase, 
whereby only larger purine nucleobase was able to form stable complex by insertion between 
the phenanthridinium subunits. 
The 11-UMP complex reorganized into the more compact form (Figure 6B) stabilized by two 
intermolecular stacking interactions – face to face and face to edge between uracil and two 
Phen. Unit and one intramolecular stacking interaction (Phen. Unit – adenine). The 
hydrophobic pocket outlined by two perpendicularly oriented phenanthridinium units and the 
alkyl linker prevented water molecules to compete with uracil from UMP in forming two 
intermolecular hydrogen bonds: one with adenine and the other with phenanthridinium 
subunit. The potential energy of the final system is about 7% lower than that of the initial. 
Furthermore, stabilization due to solvation effects also increased during the MD simulation: 
the non-polar solvent-accessible surface area decreased for about 22% and the polar solvent-
accessible surface area increased for about 6%. 
 
Figure 5. Conformation of the 11-UMP complex significantly changed during MD simulation 
in water. 
 A 
 
B 
Figure 6. The starting conformation of  11-UMP complex with the Watson-Crick type of H- 
bonds (A) changed to the conformation (B) in which the complex is stabilized by three 
intermolecular stacking interactions (▬) and two intermolecular H-bonds (▬). 
 
The 11-AMP complex (Figure 7A) also reorganized into the more stable conformation during 
MD simulations (Figure 7B). However the stabilisation due to the solvatation effects is 
insignificant, i.e. the non-polar solvent-accessible surface area of the complex decreased for 
only about 8% and the polar solvent-accessible surface area decreased for about 4%. 
 
A 
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Figure 7. The starting conformation of 11-AMP complex (A) changed to the conformation 
(B), in which covalently attached adenine was displaced by AMP from the cavity between 
two phen. units. 
The overall shape of the final 11-AMP complex (Figure 7B) is less compact (as it can be seen 
from decrease of solvent-accessible surface area) and overlapping of aromatic units is less 
pronounced in comparison to the 11-UMP complex (Figure 6B). The latter property could be 
correlated to the opposite changes in UV/vis titration experiments (Figure 2); namely three 
aromatic stacking interactions between UMP and 11 could yield hypochromic effect in 
respect to free 11, while less pronounced aromatic overlapping caused by addition of AMP to 
11 could result in hyperchromic effect. 
 
Conclusions: 
The bis-phenanthridinium – adenine derivative 11 successfully combined high affinity of 
previously known bis-intercalands
7
 towards nucleobases with the selectivity toward 
complementary nucleotide (UMP). Molecular modelling studies suggests that selectivity of 11 
toward UMP with respect to other nucleotides is most likely consequence of  organization of 
the 11-UMP complex in the compact form stabilized by efficient intra- and intermolecular 
stacking interactions (as shown by hypochromic effect in UV/Vis titration) as well as by 
intermolecular hydrogen bonds between uracil and 11. 
Other bis-phenanthridinium – nucleobase derivatives (10 and 12) were not able to distinguish 
between studied nucleotides significantly. The MD simulations of uracil-conjugate 10  as well 
as 9-UMP complex suggest that uracil due to the small aromatic surface was not able to form 
a stable conformation in which it would simultaneously form stacking interactions with the 
both phenanthridinium subunits and therefore failed to induce formation of the hydrophobic 
cavity necessary for hydrogen bonding recognition of nucleotides. On the other hand, two 
adenines attached to the derivative 12 could compete with any nucleotide added, thus 
lowering the binding constant value. 
Finally, high affinity of novel compounds 9-12 towards nucleotides makes studies of their 
interactions with single stranded and double stranded DNA/RNA sequences highly promising, 
whereby selectivity of 11 towards UMP could be even more pronounced in a case of more 
hydrophobic poly U. In addition, other bis-phenanthridinium – nucleobase derivatives could 
also reveal selective affinity and/or spectroscopic sensing toward complementary DNA/RNA 
sequences. Furthermore, all studied compounds and especially derivative 9 are expected to 
show high affinity toward ds-DNA, and consequently pronounced biological activity as many 
other bis-aromatic compounds.
20,21 
 
 
Experimental 
 
General Procedures 
1
H and 
13
C NMR spectra were recorded on on Bruker Avance DRX 500 operating at 500 
MHz. Chemical shifts () are expressed in ppm, and J values in Hz. Signal multiplicities are 
denoted as s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). The electronic 
absorption spectra of newly prepared compounds were measured on a Varian Cary 100 Bio 
spectrometer in quartz cuvettes (1 cm and 10 cm). UV-Vis titration were performed on a 
Varian Cary 100 Bio spectrometer and also on Varian Cary 50 using immersion probe with 5 
cm light path length. IR spectra were recorded on a Perkin–Elmer 297 instrument using KBr 
pellets. Fluorescence spectra were recorded on Varian Cary Eclipse fluorimeter. Mass spectra 
were obtained using Waters Micromass ZQ spectrometer as well as using Applied Biosystems 
4800 Plus MALDI TOF/TOF™ Analyzer. Preparative thin layer chromatography (TLC) was 
carried out using Kieselgel HF254 “Merck”. Melting points were determined on Kofler 
apparatus and are uncorrected. All products were characterized by NMR, IR, ESI-MS or 
HRMS. Hygroscopic character of compounds yielded elemental analyses with non–
stoichiometric amounts of water – however, since NMR spectra of final compounds were in 
accordance with other, previously prepared close analogues,
22
 proposed structures are not 
questionable. 
 
UV/Vis and fluorescence measurements 
Nucleotides were purchased from Sigma and Aldrich, and used without further purification. 
The measurements were performed in aqueous buffer solution (pH = 5, I = 0.05 mol dm
–3
, 
sodium cacodylate/HCl buffer). Under the experimental conditions used (concentration of 
compounds 9-12 ~ 10
-6
 mol dm
-3
)
 
the absorbance and fluorescence intensities of 9-12 were 
proportional to their concentrations. Spectroscopic titrations were performed at constant ionic 
strength (buffer, I = 0.05 mol dm
–3
) by adding portions of nucleotide solution into solution of 
the tested compound. Obtained data were corrected for dilution. UV/Vis titrations were 
performed using immersion probe with 5 cm light path length, which allowed measurements 
at concentration range of 10
-6
 mol dm
-3
, thus at experimental conditions comparable to 
fluorimetric titrations. It should be noted that UV/vis spectra were collected in the range  = 
260 – 300 nm, at which both, 9-12 and also nucleotides absorb light, therefore for the 
processing of the titration-induced changes in complete spectral range multivariate analysis 
program was necessary In fluorimetric titrations excitation wavelengths at max = 320 nm 
were used in order to avoid absorption of excitation light by added nucleotides and changes in 
emission at maxima were monitored. The binding constants and stoichiometries of complexes 
of 9-12 with nucleotides were calculated for the concentration range corresponding to ca. 20–
80 % complexation by non–linear least–square fitting program SPECFIT.19 
 
Molecular modeling 
Molecules were built using the module ‘Builder’ within the program InsightII,23 and using the 
option ‘Modify Torsion’ the stacking conformation was prepared for each of the molecule. 
The crystal structure of AMP was separated from crystal structure of complex with PDB-id 
code 1Z6S. 
UMP was constructed using the crystal structure of AMP as a by replacing A with U. The 
replacement was done using the module ‘Biopolymer’ within the program InsightII. The 
AMBER ff03 force field of Duan et al.
24
 and the general AMBER force field GAFF were 
used to obtain parameters for the bis-phenanthridinium-conjugates, nucleoside 
monophosphates and water molecules. The tLeap module of AMBER 9 was used to obtain 
topology and coordinate files for molecules and complexes. The each molecule was placed in 
the centre of a octahedron that was filled with TIP3P type water molecules; the water buffer 
of 8 Å was used. Besides water molecules, Cl- ions were added to neutralize the system when 
necessary Geometry optimization and molecular dynamics (MD) simulations were 
accomplished using the AMBER 9 program package.
25
 The simulation was accomplished 
using Periodic Boundary Conditions (PBC). The Particle Mesh Ewald (PME) method was 
used for calculation of electrostatic interactions. In the direct space the pairwise interactions 
were calculated within the cutoff-distance of 11 Å. Before molecular dynamics (MD) 
simulations, the system was optimized using steepest descent and conjugate gradient methods, 
1500 steps of each. After energy minimization, the system was equilibrated during 10 ps. 
During equilibration the temperature was linearly increasing from 0 to 300 K and the volume 
was held constant. The equilibrated system was then subjected to at least 8.5 ns (UMP - 11 
and AMP – 11, 13.5 ns AMP - 9) of productive unconstrained molecular dynamics simulation 
at constant temperature and volume (300 K). The time step during the simulation was 1 fs and 
temperature was held constant using Langevin dynamics with a collision frequency of 1 ps
-1
. 
The trajectories were visualized using the VMD 1.8.6 program. The RMSDs (root mean 
square deviations) between the initial conformation and those obtained during the MD 
simulation were calculated for each complex. The trajectories were divided into several stages 
(consisting of subsequent conformations with similar RMSD), and for each of this stage the 
average conformation was determined. The average conformations, as well as the final one, 
were energy minimized using the same procedure as for the initial one. The obtained 
conformations were visually compared using the InsightII software. 
 
Synthesis of compounds 
N,N’-bis-[(4’-tosylamino)-2-biphenylyl]-suberamid (1): Solution of tosyl-chloride (1.5 g, 
6.71 mmol) in 15 ml of pyridine was added dropwise during 1 h to the ice-cold solution of 
N,N’-bis-[(4’-amino)-2-biphenylyl]-suberamid16 (690 mg, 1.3 mmol) in 15 ml of pyridine. 
After adding was completed, reaction mixture heated at 50-60 ºC during 4 h. Subsequently, 
reaction mixture was allowed to cold and then poured into water. Therefore light yellow solid 
precipitated. Recrystalization from methanol gave white solid 1 (780 mg, 70 % yield). Rf 
(SiO2, 5 % MeOH in CH2Cl2) = 0.31; mp 110-112 C; 
1
H-NMR (DMSO-d6) : 1.17 (br s, 
CH2, 4 H), 1.44 (br s, CH2, 4 H), 2.10 (t, CH2, 4 H, J = 6.79 Hz), 2.32 (s, Ts-CH3, 6 H), 7.11 
(d, Ts, 4H, J = 8.57 Hz), 7.20-7.22 (m, Ar-H, 7 H), 7.27-7.29 (m, Ar-H, 2 H), 7.33-7.34 (m, 
Ar-H, 5 H), 7.39-7.41 (m, Ar-H, 2 H), 7.68-7.69 (m, Ar-H, 4 H), 9.11 (s, NH-CO, 2 H), 10.36 
(s, NH-Ts, 2 H); 
13
C-NMR (DMSO-d6) : 21.09 (Ts-CH3), 25.07, 28.57, 35.74, 119.42, 
125.95, 126.85, 127.35, 127.63, 129.65, 129.84, 130.13, 134.49, 134.99, 136.15, 137.08, 
137.16, 143.37, 171.61; IR (KBr) : 3464, 3246, 2924, 2853, 2366, 2345, 1647, 1524, 1508, 
1458, 1445, 1385, 1339, 1325, 1227, 1157, 1092, 924, 841, 814, 764, 658, 573, 546 cm
–1
; 
Anal. Calcd for C46H46N4O6S2 (Mr 815.03 gmol
-1
): C 67.72, H 5.96, N 6.87 %; Found: C 
67.36, H 5.48, N 6.70 % 
 
1,6-Bis-(8-tosylaminophenantridine-6-il)-hexane (2) was obtained by suspending of N,N’-
bis-[(4’-tosylamino)-2-biphenylil]-suberamide 1 (2 g; 2.45 mmol) in 8 ml POCl3 and heating 
reaction mixture at 100-110 °C during 3 h. Mixture was allowed to cold and poured into ice, 
and afterwards was made alkaline (pH = 8-9) by addition of 3 M NaOH water solution. 
Yellow solid precipitated and was filtered and washed with water to give pale yellow powder 
(1.8 g, 94 % yield); Rf (SiO2,10 % MeOH in CH2Cl2) = 0.52; mp 269-271 ºC; 
1
H-NMR 
(DMSO-d6) : 1.45 (br s, CH2-hexylene-chain, 4 H), 1.71 (br s, CH2-hexylene-chain, 4 H), 
2.32 (s, Ts-CH3, 6 H), 3.12 (t, CH2-hexylene-chain, 4 H, J = 6.79 Hz),7.11 (d, Ts, 4H, J = 
8.57 Hz), 7.20-7.22 (m, Ar-H, 7 H), 7.27-7.29 (m, Ar-H, 2 H), 7.33-7.34 (m, Ar-H, 5 H), 
7.39-7.41 (m, Ar-H, 2 H), 7.68-7.69 (m, Ar-H, 4 H), 9.11 (s, NH-CO, 2 H), 10.36 (s, NH-Ts, 
2 H) ppm; 
13
C-NMR (DMSO-d6) : 21.09 (Ts-CH3), 25.07, 28.57, 35.74, 119.42, 125.95, 
126.85, 127.35, 127.63, 129.65, 129.84, 130.13, 1¸134.49,134.99, 136.15, 137.08, 
137.16,143.37, 171.61 ppm; IR (KBr) : 3275, 3067, 2934, 2858, 2363, 2345, 1618, 1576, 
1535, 1491, 1448, 1389, 1348, 1242, 1161, 1092, 953, 895, 814, 762, 669, 575, 544, 473, 459 
cm
-1
; ESI-MS (m/z) found for C46H42N4O4S2 (Mr 779.0 gmol
-1
): 779.0 (M
+
+ 1); 390.2 (M
2+
+ 
2). 
 
1,6-Bis-[8-(propyltosylamino)phenanthridine-6-il]-hexane (3): 1-bromopropane (234 l; 
257 mmol; 20 equivalents) and K2CO3 (266 mg; 1.93 mmol, 20 equivalents) were suspended 
in dry DMF (10 ml). To this suspension, solution 1,6-bis-(8-tosylaminophenantridine-6-il)-
hexane (2) (100 mg; 0.128 mmol) in dry DMF (5 ml) was added dropwise during 10 min. and 
the reaction mixture was stirred during 4 days under argon atmosphere at room temperature. 
Water and CH2Cl2 were added to this suspension, the water layer was washed twice with 
CH2Cl2, organic extracts were dried over Na2SO4 and evaporated, yielding brown oil. Oily 
residue was triturated with water to give light brown precipitate that was filtered (71 mg, 
64%), washed with water and dried, and used without further purification. Pure compound 2 
was obtained by TLC (SiO2, 2% MeOH in CH2Cl2, Rf = 0.54) as white solid, additionally 
recrystalized from MeOH; mp 187-189 C; 1H-NMR (CDCl3) : 0.93 (t, CH3, 6H, J = 7.34 
Hz), 1.46-1.53 (m, CH2-hexylene-chain, CH2-propyl chain, 8 H), 1.85 (br s, CH2-hexylene-
chain, 4 H), 2.41 (s, Ts-CH3, 6 H); 3.21 (t, CH2-hexylene-chain, 4 H, J = 7.59 Hz), 3.65 (t, 
NCH2, 4 H, J = 7.04 Hz), 7.23 (d, Ts, 4H, J = 8.13 Hz), 7.45 (d, Ts, 4H), 7.54 (dd, Phen-9, 2 
H, J7-9 = 1.9 Hz, J9-10 = 8.73 Hz), 7.64 (t, Phen-2, 2 H), 7.73 (t, Phen-3, 2 H), 7.87 (d, Phen-7, 
2 H), 8.12 (d, Phen-4, 2 H, J3-4 = 8.02 Hz), 8.50 (d, Phen-1, 2 H, J1-2 = 8.02 Hz), 8.59 (d, 
Phen-10, 2 H) ppm; 
13
C-NMR (CDCl3) : 9,93 (CH3), 20,47 (Ts-CH3), 20,53 (CH2-propyl 
chain), 28,06 (CH2-hexylene-chain), 28,58 (CH2-hexylene-chain), 34,50 (CH2-hexylene-
chain), 51,18 (NCH2), 120,90 (Phen-10), 121,99, 123,39 (Phen-1), 125,05 (Phen-7), 125,50, 
126,59 (Ts), 127,05, 127,87 (Phen-3), 128,28, 128,40 (Ts), 128,63 (Phen-4),129,81, 134,01, 
142,46 ppm; IR (KBr) :3425, 3065, 2961, 2932, 2874, 2858, 2363, 2345, 1599, 1572, 1528, 
1479, 1458, 1344, 1238, 1213, 1167, 1090, 1074, 1020, 964, 872, 812, 766, 725, 708, 667, 
642, 582, 550 cm
-1
; Anal. Calcd for C52H54N4O4S2 (Mr = 863.16): C 72.36, H 6.31, N 6.49 %; 
Found: C 72.05, H 6.22, N 6.54 %; ESI-MS (m/z) found for C52H54N4O4S2 (Mr 863.16 gmol
-
1
): 863.0 (M
+
+ 1); 432.3 (M
2+
+ 2); 192.2 (M
2+
+ 3). 
 
1-[8-(3-bromopropyltosyl)aminophenanthridine-6-il]-6-[8-
(propyltosyl)aminophenanthridine-6-il]-hexane (4): 1-bromopropane (56 l; 0.617 mmol; 
1.6 equivalents) and K2CO3 (133 mg; 0.964 mmol, 2.5 equivalents) were suspended in dry 
DMF (10 ml). To this suspension, solution 1,6-bis-(8-tosylaminophenantridine-6-il)-hexane 
(2) (300 mg; 0.386 mmol) in dry DMF (5 ml) was added dropwise during 10 min. and the 
reaction mixture was stirred during 7 days under argon atmosphere at room temperature. 
Then, 1,3-dibromopropane (525 l, 5.14 mmol, 13 equivalents) and K2CO3 (533 mg; 3.86 
mmol, 10 equivalents) were added to reaction mixture, that was stirred during next two days 
under argon atmosphere at room temperature. Water and CH2Cl2 were added to this 
suspension, the water layer was washed twice with CH2Cl2, organic extracts were dried over 
Na2SO4 and evaporated, yielding brown oil. Oily residue was triturated with water to give 826 
mg of light brown precipitate that was filtered (160 mg, 44%), washed with water and dried. 
Pure compound 4 was obtained by TLC (SiO2, 2% MeOH in CH2Cl2, Rf = 0.54) as white 
solid (160 mg, 44 %); mp 198-200 ºC; 1H-NMR (CDCl3) : 0.92 (t, CH3, 3H, J = 7.38Hz) 
1.44-1.53 (m, CH2-hexylene-chain, CH2-propyl chain, 6 H), 1.84 (br s, CH2-hexylene-chain, 4 
H), 2.08 (m, CH2-propylene chain, 2 H), 2.40 (s, Ts-CH3, 6 H), 3.22 (t, CH2-hexylene-chain, 4 
H, J = 6.19 Hz), 3.45 (t, CH2Br, 2 H, J = 6.36 Hz), 3.64 (t, NCH2-propyl chain, 2 H, J = 6.98 
Hz), 3.83 (t, NCH2-propylene chain, 2 H, J = 6.57 Hz), 7.22 (d, Ts, 4H, J = 8.02 Hz), 7.43 (m, 
Ts, 4H), 7.51-7.54 (m, Phen-9, 2 H), 7.63 (m, Phen-2, 2 H), 7.73 (t, Phen-3, 2 H), 7.85-7.89 
(m, Phen-7, 2 H), 8.12 (d, Phen-4, 2 H, J3-4 = 7.84 Hz), 8.49 (d, Phen-1, 2 H, J1-2 = 7.64 Hz), 
8.56-8.60 (m, Phen-10, 2 H) ppm; 
13
C-NMR (CDCl3) : 11.03 (CH3), 21.52(Ts-CH3), 21.62, 
29.19, 29.25, 29.57, 29.85, 31.71, 49.26, 52.24, 76.79, 77.00, 77.21, 122.03, 123.02, 123.12, 
123.54, 123.77, 125.30, 125.36, 125.96, 126.06, 126.25, 126.36, 126.90, 127.65, 127.72, 
129.25, 129.51, 129.61, 132.23, 132.37, 134.53, 135.06, 138.17, 143.60, 143.92, 161.72, 
161.82 ppm; IR (KBr) : 3452, 2926, 2854, 2363, 2345, 1684, 1647, 1541, 1508, 1340, 1163, 
1090, 964, 812, 766, 669, 582, 548, 473 cm
-1
; (MALDI / TOF-HR MS) m/z: 941.2756 (cald. 
for C52H53BrN4O4S2: 941.2764). 
 
1,6-Bis-[8-(3-bromopropyltosylamino)phenanthridine-6-il]-hexane (5) was obtained as 
side product during preparation of 4 as a white powder (30 mg, 8% yield), Rf (SiO2, 2% 
MeOH in CH2Cl2) = 0.25; mp 205-209 ºC; 
1
H-NMR (CDCl3) : 1.54 (br s, Phen-CH2, 4 H), 
1.85 (br s, CH2-hexylene-chain, 4 H). 2.07 (t, CH2, 2 H), 2.41 (s, Ts-CH3, 6 H), 3.24 (br s, 
CH2-hexylene-chain, 4 H), 3.45 (t, Br-CH2, 4 H, J = 6.91 Hz) 3.84 (t, NCH2, 4 H, J = 6,91 
Hz), 7.22 (d, Ts, 4H, J = 7.99 Hz), 7.42 (d, Ts, 4H), 7.53 (d, Phen-9, 2 H, J9-10 = 8.77 Hz), 
7.64 (m, Phen-2, 2 H), 7.73 (m, Phen-3, 2 H), 7.88 (s, Phen-7, 2 H), 8.15 (br s, Phen-4, 2 H), 
8.49 (d, Phen-1, 2 H, J1-2 = 8.22 Hz), 8.58 (d, Phen-10, 2 H) ppm; 
13
C-NMR (CDCl3) : 
21.53, 29.12, 29.59, 29.83, 31.76, 48.21, 49.29, 122.03, 123.01, 123.74, 125.45, 126.00, 
126.77, 126.80, 127.74, 129.16, 129.60, 130.47, 132.33, 134.67, 138.15, 143.89, 161.65 ppm; 
IR (KBr) : 3447, 3065, 3032, 2926, 2854, 2365, 2345, 1717, 1653, 1541, 1458, 1346, 1242, 
1163, 1092, 949, 812, 764, 725, 708, 667, 582, 548, 419, 397 cm
-1
; (MALDI / TOF - HR MS) 
m/z: 1019.1891 (cald. for C52H52Br2N4O4S2: 1019.1869). 
 
1-[8-(3-(urac-1-il)propyltosyl)aminophenanthridine-6-il]-6-[8-
(propyltosyl)aminophenanthridine-6-il]hexane (6): Uracil (107 mg; 0.955 mmol, 10 
equivalents) that was previously dried, and NaH (38 mg, 60% w.w., 0.955 mmol, 10 
equivalents) were suspended in dry DMF (5 ml) and stirred during 1 h in argon atmosphere at 
room temperature. To this suspension, a solution of 1-[8-(3-
bromopropyltosyl)aminophenanthridine-6-il]-6-[8-(propyltosyl)aminophenanthridine-6-il]-
hexane 4 (90 mg; 0.095 mmol) in dry DMF (10 ml) was added dropwise and the reaction 
mixture was stirred during 48 hours under argon atmosphere at 50C. Then, water and CH2Cl2 
were carefully added to this suspension. The water layer was washed twice with CH2Cl2, 
organic extracts were dried over Na2SO4 and evaporated, yielding oily residue that was 
trituated with water to give 95 mg of white precipitate. Precipitate was filtered, washed with 
water and dried; and then purified by TLC (SiO2, 10% MeOH in CH2Cl2, Rf = 0.55). 
Compound 6 was obtained as white solid (35 mg, 37 % yield); mp 200-203 C; 1H-NMR 
(CDCl3) : 0.90 (t, CH3, 3H, J = 7,81Hz), 1.52 (m, CH2-hexylene-chain, CH2-propyl chain, 6 
H), 1.84 (m, CH2-hexylene-chain, CH2-propylene chain, 6 H), 2.39 (s, Ts-CH3, 6 H), 3.19-
3.24 (m, CH2-hexylene-chain, 4 H) 3.62 (t, NTsCH2-propyl chain, 2 H, J = 6.75 Hz), 3,72 (t, 
NTsCH2-propylene chain, 2 H, J = 6.32 Hz), 3.85 (t, uracil-NCH2-propylene chain, 2H, J = 
6.70 Hz), 5.66 (d, uracil-5, 1 H, J5-6 = 7.85 Hz), 7.21 (d, Ts, 4H, J = 8.12 Hz), 7.31 (d, uracil-
6, 1 H), 7.36-7.46 (m, Ts, Phen-9, 5H), 7.51 (dd, Phen-containing-base-9, 1 H, J7-9 = 1.95 
Hz), 7.59-7.74 (m, Phen-2, Phen-3, 4 H), 7.83 (d, Phen-containing-base-7, 1 H), 7.94 (d, 
Phen-7, 1 H), 8.10 (d, Phen-4, 2 H, J3-4 = 7.29 Hz), 8,47 (d, Phen-1, 2 H, J1-2 = 8.13 Hz), 8.54 
(d, Phen-10, 1 H, J9-10 = 8.89 Hz), 8.58 (d, Phen-containing-base-10, 1 H), 8.78 (s, U-NH, 1 
H) ppm; 
13
C-NMR (CDCl3) : 11.23 (CH3), 21.73 (TsCH3), 21.75 (TsCH3), 21.81 (CH2-
propyl chain), 27.41 (CH2-propylene chain), 29.21 (CH2-hexylene-chain), 29.76 (CH2-
hexylene-chain), 36.05 (CH2-hexylene-chain), 46.51 (uracil-NCH2-propylene chain). 47.69 
(NTsCH2-propylene chain), 52.35 (NTsCH2-propyl chain), 102.27 (uracil-5), 114.76, 121.30, 
122.22 (Phen-1), 122.23 (Phen-1), 123.1, 123.29, 123.7 (Phen-10), 124.1 (Phen-10), 125.69, 
126.11, 126.85, 126.99, 127.84, 127.95, 129.44, 129.72, 129.87, 132.35, 132.70, 134.27, 
135.27, 137.45, 143.8, 144.35, 145.24 (uracil-6), 150.74, 161.75, 163.51 ppm; IR (KBr) 
:3462, 2928, 2853, 2361, 2343, 1686, 1647, 1541, 1508, 1458, 1385, 1340, 1159, 1092, 812, 
766, 723, 669, 584, 546 cm
-1
; ESI-MS (m/z) found for C56H56N6O6S2 (Mr 973.24 gmol
-1
): 
973.1 (M
+
+ 1), 487.3 (M
2+
+ 2). 
 
1-[8-(9-(aden-1-il)propyltosyl)aminophenanthridine-6-il]-6-[8-
(propyltosyl)aminophenanthridine-6-il]hexane (7) was obtained as described for 6; 1-[8-(3-
bromopropyltosyl)aminophenanthridine-6-il]-6-[8-(propyltosyl)aminophenanthridine-6-il]-
hexane 4 (130 mg; 0.138 mmol), adenine (187 mg; 1.38 mmol, 10 equivalents) and NaH (55 
mg, 60% w.w., 1.38 mmol, 10 equivalents) in dry DMF (10 + 10 ml) gave white powder 7 (50 
mg, 36 % yield), Rf (SiO2, 10% MeOH in CH2Cl2) = 0.48; mp 184-186 C; 
1
H-NMR (CDCl3) 
: 0.88 (t, CH3, 3H, J = 7.31 Hz), 1.45 (ps. q. CH2-propyl-chain, 2 H), 1.51 (br s, CH2-
hexylene-chain, 4 H), 1.83 (br s, CH2-hexylene-chain, 4 H), 2.05 (br s, CH2-propylene-chain, 
2H), 2.36 (s, Ts-CH3, 3 H), 2.37 (s, Ts-CH3, 3 H), 3.19 (m, CH2-hexylene-chain, 4 H), 3.61 (t, 
NTsCH2-propyl-chain, 2 H, J = 7.02 Hz), 3.68 (t, NTsCH2-propylene-chain, 2 H, J = 5.93 
Hz), 4.30 (t, adenine-NCH2-propylene-chain, 2H, J = 6.34 Hz), 5.80 (br s, adenine-NH2, 2 H), 
7.16-7.19 (m, Ts, 4H), 7.34 (d, Ts, 2H, J = 7.95 Hz), 7.42 (d, Ts-Phen-containing-base-, 2H, J 
= 7.96 Hz), 7.45 (d, Phen-containing-base-9, 1H, J9-10 = 8.63 Hz), 7.48 (d, Phen-9, 1H, J9-10 = 
8.73 Hz), 7.57 (ps. t., Phen-containing-base-2, 1H), 7.60 (ps. t., Phen-2, 1H), 7.65 (ps. t., 
Phen-containing-base-3, 1H), 7.70 (ps. t., Phen-3, 1H), 7.82 (s, Phen-containing-base-7, 1 H), 
7.86 (s, adenine-8, 1 H), 7.89 (s, Phen-7, 1 H), 8.06 (d, Phen-containing-base-4, 1H, J3-4 = 
8.01 Hz), 8.08 (d, Phen-4, 1H, J3-4 = 8.00 Hz), 8.21 (s, adenine-2, 1 H), 8.42 (d, Phen-
containing-base-1, 1 H, J1-2 = 8.04 Hz), 8.46 (d, Phen-1, 1 H, J1-2 = 8.10 Hz), 8.50 (d, Phen-
containing-base-10, 1 H), 8.55 (d, Phen-10, 1 H) ppm; 
13
C-NMR (CDCl3) : 11.25 (CH3), 
21.72 (TsCH3), 21.89 (CH2-propyl-chain), 28.57 (CH2-propylene-chain), 29.17 (CH2-
hexylene-chain), 29.25 (CH2-hexylene-chain), 29.80 (CH2-hexylene-chain), 29.85 (CH2-
hexylene-chain), 36.16 (CH2-hexylene-chain), 36.23 (CH2-hexylene-chain), 41.20 (adenine-
NCH2-propylene-chain), 47.94 (NTsCH2-propylene-chain), 52.52 (NTsCH2-propyl-chain), 
122.20 (Phen-containing-base-1), 122.25 (Phen-1), 123.15, 123.28, 123.67 (Phen-containing-
base-10), 124.04 (Phen-10), 125.75, 125.80, 126.16 (Phen-containing-base-7), 126.61 (Phen-
7), 126.81 (Phen-containing-base-2), 126.92 (Phen-2), 127.93 (Ts), 127.99 (Ts), 129.16 
(Phen-containing-base-3), 129.36 (Phen-3), 129.71 (Ts), 129.80 (adenine-8), 129.84 (Ts), 
129.91 (Phen-containing-base-4), 130.04 (Phen-4), 130.47 (Phen-containing-base-9), 130.54 
(Phen-9), 132.31, 132.65, 134.62, 135.50, 137.74, 138.28, 143.76, 144.16, 144.24, 144.29, 
152.98 (adenine-2), 155.64, 161.69, 161.88 ppm; IR (KBr) : 3448, 2959, 2932, 2856, 2361, 
2343, 1653, 1541, 1508, 1458, 1340, 1157, 1090, 1072, 951, 812, 762, 723, 706, 665, 582, 
548 cm
-1
; ESI-MS (m/z) found for C57H57N9O4S2 (Mr 996.28 gmol
-1
): 996.3 (M
+
+ 1), 498.8 
(M
2+
+ 2). 
 
1,6-Bis-[8-(3-(aden-9-il)propyltosylamino)phenanthridine-6-il]-hexane (8) was obtained 
as described for 6; 1,6-Bis-[8-(3-bromopropyltosylamino)phenanthridine-6-il]-hexane 5 (25 
mg; 0.024 mmol), adenine (40 mg; 0.29 mmol, 10 equivalents) and NaH (12 mg, 60% w.w., 
0.29 mmol, 10 equivalents) in dry DMF (5 + 5 ml) gave white powder 8 (20 mg, 70 % yield), 
Rf (SiO2, 10% MeOH in CH2Cl2) = 0.28; mp 151-155 C; 
1
H-NMR (CDCl3) : 1.53 (br s, 
CH2-hexylene-chain, 4 H), 1.84 (br s, CH2-hexylene-chain, 4 H), 2.06 (t, CH2-propylene-
chain, 4 H, J= 6.16 Hz), 2.38 (s, Ts-CH3, 6 H), 3.22 (t, Phen-CH2-hexylene-chain, 4 H, J = 
7.69), 3.63 (t, NTsCH2-propylene-chain, 4 H, J = 5.98 Hz), 4,33 (t, adenine-NCH2-propylene-
chain, 4 H, J = 6.29 Hz), 6.41 (br s, adenine-NH2, 4 H), 7.19 (d, Ts, 4H, J = 8.11 Hz), 7.36 
(d, Ts, 2H, J = 8.23 Hz), 7.43 (dd, Phen-9, 2 H, J7-9 = 1.99 Hz, J9-10 = 8.82 Hz), 7.61 (t, Phen-
2, 2 H), 7.70 (t, Phen-3, 2 H), 7.89 (s, Phen-7, adenine-8, 4 H), 8.09 (dd, Phen-4, 2 H, J2-4 = 
0.98 Hz, J3-4 = 8.12 Hz), 8.18 (s, adenine-2, 2 H), 8.45 (d, Phen-1, 2 H, J1-2 = 7.50 Hz), 8.54 
(d, Phen-10, 2 H) ppm; 
13
C-NMR (CDCl3) : 21.58 (TsCH3), 28.14, 29.03, 29.52, 29.70, 
35.93. 41.04, 47.46, 122.04, 122.87, 123.85, 125.51, 126.34, 126.76, 127.72, 129.21, 129.66. 
129.80, 132.38, 134.09, 137.29, 143.90, 144.12, 152.44, 155.51, 161.62 ppm; IR (KBr) : 
3421, 2922, 2851, 2363, 2345, 1647, 1597, 1574, 1475, 1420, 1385, 1340, 1304, 1244, 1159, 
1109, 1088, 991, 935, 872, 814, 764, 725, 698, 667, 582, 544cm
-1
; ESI-MS (m/z) found for 
C62H60N14O4S2 (Mr 1129.39 gmol
-1
): 1129.3 (M
+
+ 1), 565.4 (M
2+
+ 2), 377.4 (M
3+
+ 3). 
 
1,6-Bis-[8-(propylamino)phenanthridine-6-il]-hexane (9) was obtained by heating solution 
of 1,6-bis-[8-(propyltosylamino)phenanthridine-6-il]-hexane 3 (27 mg, 0.032 mmol) in 
mixture of 1 ml conc. H2SO4 and 2 ml conc. acetic acid under reflux at 80-100 C for 2 h. 
Reaction mixture was cooled, poured on ice and made alkaline (pH = 8-9) by addition of 2 M 
NaOH. The obtained yellow-brown solid was precipitated, filtered and washed with lots of 
water to afford pure compound 9 (5 mg, 28 % yield); mp 221-224 ºC; Rf (SiO2, 10% MeOH 
in CH2Cl2) = 0.49; 
1
H-NMR (DMSO-d6) : 0.94 (t, CH3, 6H, J = 7.47 Hz), 1.57-1.64 (m, 
CH2-hexylene, CH2-propyl chain, 8 H), 1.89 (br s, CH2-hexylene, 4 H), 3.12 (br s, CH2-
hexylene, 4 H), 6.28 (br s, NH, 2 H), 7.12 (s, Phen-7, 2 H), 7.27 (d, Phen-9, 2 H, J9-10 = 7.83 
Hz), 7.46-7.53 (m, Phen-2, Phen-3, 4 H), 7.88 (m, Phen-4, 2 H), 8.49 (m, Phen-1, Phen-10, 4 
H) ppm; IR (KBr) : 3447, 3246, 2961, 2926, 2854, 2361, 2334, 1653, 1618, 1541, 1508, 
1458, 1387, 1340, 1315, 1256, 1232, 1205, 1140, 824, 762, 669, 598, 517 cm
-1
; (MALDI / 
TOF-HR MS) m/z: 555.3493 (cald. for C38H42N4: 555.3482). 
 
1-[8-(3-(urac-1-il)propyl)aminophenanthridine-6-il]-6-[8-(propyl) aminophenanthridine-
6-il]hexane (10) was obtained as described for 9; 1-[8-(3-(urac-1-
il)propyltosyl)aminophenanthridine-6-il]-6-[8-(propyltosyl)aminophenanthridine-6-il]hexane 
6 (40 mg, 0.04 mmol) in 1 ml conc. H2SO4 gave yellow powder gave yellow powder 10 (15 
mg, 53 % yield); mp 108-110 ºC; Rf (SiO2, 10% MeOH in CH2Cl2) = 0.39; 
1
H-NMR (DMSO-
d6) : 
1
H-NMR (DMSO-d6) : 0.94 (t, CH3, 3H, J = 7.40 Hz), 1.59 (m, CH2-hexylene-chain, 
CH2-propyl chain, 6 H), 1.90 (m, CH2-hexylene-chain, CH2-propylene chain, 6 H), 3.12 (m, 
NCH2, 2 H), 3.,21 (m, CH2-hexylene-chain, 4 H), 3.79 (t, uracil-NCH2-propylene chain, 2H, J 
= 6.30 Hz), 5.54 (d, uracil-5, 1 H, J5-6 = 7.86 Hz), 6.27 (NH, br s, 2 H), 7.14 (dd, Phen-9, 2H, 
), 7.25 (s, Phen-7, 1 H), 7.28 (s, Phen-7, 1 H),7.50 (m, Phen-2, Phen-3, 4 H), 7.62 (d, uracil-6, 
1 H), 7.87 (d, Phen-4, 2 H), 8.51 (m, Phen-1, Phen-10), 11.25 (s, uracil-NH, 1 H) ppm; 
13
C-
NMR (DMSO-d6) : 11.23 (CH3), 21.81 (CH2-propyl chain), 27.41 (CH2-propylene chain), 
29.21 (Phen-CH2), 29.76 (Phen-CH2), 36.05 (Phen-CH2), 46.51 (uracil-NCH2-propylene 
chain). 47.69 (NHCH2-propylene chain), 52.35 (NHCH2-propyl chain), 102.27 (uracil-5); IR 
(KBr) : 3398, 3057, 2926, 2853, 2363, 2345, 1684, 1655, 1618, 1541, 1508, 1458, 1387, 
1340, 1259, 1232, 1200, 1136, 1034, 997, 949, 864, 824, 760, 721, 669, 617, 548 cm
-1
; 
(MALDI / TOF-HR MS) m/z: 665.3580 (cald. for C42H44N6O2: 665.3599). 
 
1-[8-(9-(aden-1-il)propyl)aminophenanthridine-6-il]-6-[8-(propyl)aminophenanthridine-
6-il]hexane (11) was obtained as described for 9; 1-[8-(9-(aden-1-
il)propyltosyl)aminophenanthridine-6-il]-6-[8-(propyltosyl)aminophenanthridine-6-il]hexane 
7 (45 mg, 0.045 mmol) in 1 ml conc. H2SO4 and 2 ml conc. acetic acid gave yellow powder 
gave yellow powder 11 (15 mg, 50 % yield); Rf (SiO2, 10% MeOH in CH2Cl2) = 0.32; mp 
119-122 ºC; 1H-NMR (DMSO-d6) : 0.90 (t, CH3, 3H, J = 7.39 Hz), 1.51-1.61 (m, CH2-
hexylene-chain, CH2-propyl chain, 6 H), 1.88 (br s, Phen-CH2, 4 H), 2.13 (m, CH2-propylene-
chain, 2H), 3.08 (m, NHCH2-propyl chain, 2 H), 3.16-3.21(m, Phen-CH2, NHCH2-propylene 
chain, 6 H), 4.27 (t, adenine-NCH2-propylene-chain, 2H, J = 6,75 Hz), 6.26 (br s, NH, 1H), 
6.39 (br s, NH, 1H), 7.10 (s, Phen-7, 2H), 7.21-7.29 (m, adenine-NH2, Phen-9, Phen-7, 5 H), 
7.48-7.52 (m, Phen-2, Phen-3, 4 H), 7.86 (m, Phen-4, H), 8.14 (br s, adenine-2, adenine-8, 
2H), 8.46-8.52 (m, Phen-1, Phen-10, 4 H) ppm; 
13
C-NMR (DMSO-d6) : 11.80 (CH3), 21.83, 
28.07, 28.21, 28.92, 29.19, 29.29, 41.21, 44.70, 103.02, 103.32, 114.63, 119.04, 119.65, 
120.59, 121.29, 121.36, 122.63, 122.93, 123.74, 123.86, 124.14, 124.22, 126.20. 126.24, 
126.31, 126.73, 126.75, 129.05, 129.08, 129.62, 141.50, 141.58, 148.36. 148.70, 149.79, 
152.55, 156.15, 160.59, 160.70 ppm; IR (KBr) : 3447, 2928, 2853, 2361, 2343, 1869, 1772, 
1734, 1647, 1618, 1541, 1508, 1458, 1387, 1339, 1315, 1259, 1232, 1200, 822, 760, 669, 650, 
519 cm
-1
; (MALDI / TOF-HR MS) m/z: 688.3886 (cald. for C43H45N9: 688.3871). 
 
1,6-Bis-[8-(3-(aden-9-il)propylamino)phenanthridine-6-il]-hexane (12) was obtained as 
described for 9; 1,6-bis-[8-(3-(aden-9-il)propyltosylamino)phenanthridine-6-il]-hexane 8 (30 
mg, 0.027 mmol) in 1 ml conc. H2SO4 and 2 ml conc. acetic acid gave yellow powder gave 
yellow powder 12 (17 mg, 77 % yield); Rf (SiO2, 10% MeOH in CH2Cl2) = 0.45 mp 147-149 
ºC; 1H-NMR (DMSO-d6) : 11.53 (br s, CH2-hexylene-chain, 4 H), 1.85 (br s, CH2-hexylene-
chain, 4 H); 2.26 (m, CH2-propylene-chain, 4H), 3,15 (m, CH2-hexylene-chain, NCH2, 8 H), 
4.26 (t, adenine-NCH2-propylene-chain, 4 H, J = 6.68 Hz), 6.38 (br s, NH, 2 H), 6.98 (s, 
Phen-7, 2H), 7.22 (m, adenine-NH2, Phen-9, 6 H), 7.48-7.51 (m, Phen-2, Phen-3, 4 H), 7.86 
(m, Phen-4, H), 8.12 (s, adenine, 2H), 8.13 (s, adenine, 2H), 8.44-8.51 (m, Phen-1, Phen-10, 4 
H) ppm; 
13
C-NMR (DMSO-d6) : 27.91, 28.7, 29.08, 35.11, 38.28, 41.01, 119.44, 121.33, 
123.71, 123.95, 126.1, 126.53, 128.92, 130.79, 133.99, 138.37, 141.14, 141.4, 142.18, 148.18, 
149.57, 155.99, 158.99, 160.45 ppm; IR (KBr) : 3337, 3200, 2924, 2852, 1640, 1619, 1575, 
1541, 1479, 1462, 1420, 1395, 1335, 1308, 1240, 1210, 1178, 830, 800, 762, 730, 660 cm
-1
; 
(MALDI / TOF-HR MS) m/z: 821.4279 (cald. for C48H48N14: 821.4259). 
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